Sep 2, 2026 · 40 min
Moderna turns tumor mutations into personalized cancer vaccines
Inside Moderna’s Personalized Cancer Vaccine
The episode examines whether individualized mRNA treatment can move from promising melanoma results to a scalable, regulated form of cancer care.
- 1Moderna’s Phase 3 melanoma results suggest a personalized vaccine can strengthen Keytruda’s effect against cancer.
- 2Each vaccine uses tumor mutations to select targets, then moves from biopsy to administration in about 42 days.
- 3Scaling personalized treatment depends on industrial manufacturing, process-based regulation, and evidence across additional cancers and diseases.
Don't miss
Bancel explains how Moderna aims to produce a patient-specific vaccine in about 42 days from biopsy, using tumor information rather than engineered immune cells.
The brief
Moderna CEO Stéphane Bancel discusses positive Phase 3 melanoma results for an individualized mRNA vaccine developed with Merck alongside Keytruda.
The treatment is designed from each patient’s tumor mutations, selecting as many as 34 targets to teach the immune system which cancer signals to recognize.
The central operational challenge is speed: Moderna says it can move from biopsy to a ready-to-administer vaccine in about 42 days, without re-engineering immune cells.
Personalization also complicates scale and oversight, prompting discussion of factory capacity, pricing, and a regulatory framework focused on the process rather than each sequence.
Bancel describes melanoma as an early test of a broader platform that could extend into other cancers, rare diseases, and shared or individualized autoimmune treatments.
Featuring
Stéphane Bancel
Keytruda
Food and Drug Administration
MassachusettsListen to the full episode and explore every guest, topic, and moment on PodLume.